Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS A for Consolidation in Post-Transplant Hodgkin Lymphoma BOTHELL, Wash. & OSAKA, Japan-- -- Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced that patients with Hodgkin lymphoma who received ADCETRIS as consolidation therapy immediately following an autologous stem cell transplantation lived significantly longer without disease progression compared to patients who received placebo.
http://ift.tt/YFOcpC
http://ift.tt/YFOcpC
No comments:
Post a Comment